Revefenacin vs Benztropine — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Anticholinergic

Revefenacin

Brand: YUPELRI

First FDA approval: 2018-12-03

Anticholinergic

Benztropine

First FDA approval: 1992-01-23

Lowest NADACAcquisition cost floor across all NDCs

$17.49Per unit

$0.067Per unit

Average NADACAcross all dosage forms and strengths

$17.49Up to $17.49

$0.080Up to $0.095

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

1228 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$11.8MFull year

$35.4MFull year

Part D claims (CY24)Total fills, all strengths

9K3K beneficiaries

2.9M455K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$1,322Per claim, all NDCs

$12Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

36Minimal friction

348Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

DiscontinuedSee drug profile

Generic availableFDA Orange Book

NoBrand-only

Yes12 manufacturers